AFP
VRTX icon

Ausdal Financial Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Ausdal Financial Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$424K Sell
854
-72
-8% -$31.9K 0.02% 691
2026
Q1 		$413K Sell
926
-12
-1% -$5.6K 0.02% 655
2025
Q4 		$425K Sell
938
-575
-38% -$248K 0.02% 613
2025
Q3 		$593K Buy
1,513
+743
+96% +$311K 0.03% 501
2025
Q2 		$343K Sell
770
-10
-1% -$4.61K 0.02% 517
2025
Q1 		$378K Buy
780
+23
+3% +$10.7K 0.03% 447
2024
Q4 		$305K Buy
757
+43
+6% +$19.9K 0.03% 445
2024
Q3 		$332K Buy
714
+30
+4% +$14.4K 0.03% 389
2024
Q2 		$321K Buy
684
+97
+17% +$42.1K 0.03% 369
2024
Q1 		$245K Buy
587
+94
+19% +$39.7K 0.03% 407
2023
Q4 		$201K Buy
+493
New +$182K 0.02% 425
2022
Q1 		– Sell
-14,981
Closed -$3.29M – 530
2021
Q4 		$3.29M Buy
+14,981
New +$2.91M 0.44% 62
2016
Q1 		– Sell
-31
Closed -$4K – 1011
2015
Q4 		$4K Buy
+31
New +$3.74K ﹤0.01% 1134

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Ausdal Financial Partners's VRTX Position: Q2 2026 in Review

Ausdal Financial Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 7.8% in Q2 2026, selling an estimated $31.9K and leaving 854 shares worth $424K. The position accounts for 0.02% of the portfolio, ranked #691.

Ausdal Financial Partners first reported a position in VRTX in Q4 2015 and has held it in 13 quarters since. The position peaked at $3.29M in Q4 2021. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Ausdal Financial Partners held 854 shares of Vertex Pharmaceuticals worth $424K as of Q2 2026.
  • Ausdal Financial Partners sold 72 Vertex Pharmaceuticals shares in Q2 2026, an estimated $31.9K.
  • Vertex Pharmaceuticals made up 0.02% of Ausdal Financial Partners's portfolio in Q2 2026, its #691 holding.
  • Ausdal Financial Partners first reported a position in Vertex Pharmaceuticals in Q4 2015 and has held it in 13 quarters since.
  • Ausdal Financial Partners's Vertex Pharmaceuticals position peaked at $3.29M in Q4 2021.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Ausdal Financial Partners's 13F filing for Q2 2026, filed 14 Aug 2026.